Your browser doesn't support javascript.
loading
Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation.
Lage, Nayara Almeida; de Paiva, Mayara Rodrigues Brandão; Vasconcelos-Santos, Daniel Vitor; Machado, Renes Resende; Fialho, Sílvia Ligório; Silva-Cunha, Armando.
Afiliação
  • Lage NA; Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
  • de Paiva MRB; Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
  • Vasconcelos-Santos DV; Research and Development, Ezequiel Dias Foundation, Belo Horizonte 30510-010, Brazil.
  • Machado RR; Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte 30130-100, Brazil.
  • Fialho SL; Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
  • Silva-Cunha A; Research and Development, Ezequiel Dias Foundation, Belo Horizonte 30510-010, Brazil.
Pharmaceutics ; 15(1)2023 Jan 05.
Article em En | MEDLINE | ID: mdl-36678822
Mometasone furoate (MF) is a medium-potency synthetic glucocorticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. However, its role in the treatment of ocular inflammation has not yet been explored. This work investigated the anti-inflammatory activity of MF in ocular tissues. First, the in vivo safety of the intravitreal (IVT) injection of MF (80, 160, and 240 µg) was evaluated via clinical examination (including the assessment of intraocular pressure), electroretinography (ERG), and histopathology. Second, MF was tested in an experimental model of bacillus Calmette-Guérin (BCG)-induced uveitis in Wistar rats. Intraocular inflammation was then evaluated via a slit-lamp and fundus examination, ERG, histopathology, and the quantification of pro-inflammatory markers. Intravitreal MF showed no toxicity in all the investigated doses, with 160 µg leading to attenuated disease progression and improvement in clinical, morphological, and functional parameters. There was a significant reduction in the levels of inflammatory markers (myeloperoxidase, interleukins 6 and 1ß, CXCL-1, and tumor necrosis factor-alpha) when compared to the levels in untreated animals. Therefore, MF should be further investigated as a promising drug for the treatment of ocular inflammation.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2023 Tipo de documento: Article